Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01684397
Show Display Options
Rank Status Study
1 Recruiting Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Biological: bevacizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years